Table 1. Regression model for "time to rebound”.
| Coeff | P-value | 95%CI-lower | 95%CI-upper | |
|---|---|---|---|---|
| Vaccine /placebo arm | 1,228 | 0,103 | -0,265 | 2,721 |
| Disulfiram/ no disulfiram administration | -0,075 | 0,919 | -1,579 | 1,429 |
| HLA protective / non- protective | -0,429 | 0,551 | -1,888 | 1,031 |
| Viral Load pre cART | 0,000 | 0,725 | 0,000 | 0,000 |
| CD4 w0-STI | -0,001 | 0,360 | -0,003 | 0,001 |
| Magnitude w0-STI (SFC/106 PMBC) |
0,000 | 0,762 | 0,000 | 0,000 |
| Magnitude w12-STI (SFC/106 PMBC) |
0,000 | 0,572 | 0,000 | 0,000 |
| Proviral DNA before vaccination (HIV DNA copies/106 CD4 cells) |
-0,003 | 0,029 | -0,005 | 0,000 |
| Residual Viremia baseline | 0,094 | 0,650 | -0,338 | 0,526 |
| Number of gag HLA-associated escape mutations | -0,926 | 0,751 | -6,887 | 5,036 |
Regression model for the dependent variable "time to rebound” (weeks until detectable plasma viremia) was performed on all the individuals undergoing STI (n = 28) and including the following covariates: harboring protective HLA alleles (B*27, B*57 and B*51 (n = 14)), MVA-B vaccination (n = 19), magnitude of HIV-1 specific T cell responses at STI-start (n = 26) and after 12 weeks into STI (n = 24), disulfiram administration (n = 12), CTL virus adaptation (number of total Gag polymorphism and number of HLA-associated escape mutations in Gag) (n = 26), pre-HAART pVL (n = 25), CD4 cell counts (n = 28), residual viremia (n = 18) and levels of proviral HIV-1 DNA at the beginning of the study (n = 18). Coefficients and p-values are shown.